biologics
ACG Releases Updated EoE Guideline
The ACG published a newly updated guideline on the diagnosis and management of eosinophilic esophagitis.
MAY 15, 2025
Biologic De-escalation Common and Works for Some Patients
A large study of biologics de-escalation in patients with CD shows that the practice is common and apparently ...
APRIL 7, 2025
Non–Anti-TNF Agents Safe as 1st-Line Rx Before Anti-TNFs
Treatment with vedolizumab or ustekinumab in CD, or vedolizumab in UC, followed by an anti–TNF was found to ...
JANUARY 3, 2025
IBD Clinical Trials at a Crossroads
Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.
OCTOBER 22, 2024
FDA Approves Fourth Ustekinumab Biosimilar, Otulfi
The FDA has approved ustekinumab-aauz (Otulfi, Fresenius Kabi/Formycon), a biosimilar to ustekinumab (Stelara, ...
OCTOBER 7, 2024
Malnutrition Is Endemic to IBD, but Can Be Managed
Correcting the harms of malnutrition in inflammatory bowel disease often leads to better response to biologic ...
AUGUST 21, 2024
Treating Fibrostenosing Crohn’s and Optimizing Biologic Timing After Temporary Diversion Following Resection
This month’s The Regueiro Report focuses on best practices in two different scenarios of Crohn’s ...
AUGUST 16, 2024
What to Do for Asymptomatic Patients With IBD? A Comprehensive Study Provides Answers
It is appropriate to change therapy for asymptomatic patients with IBD to achieve endoscopic healing in most ...
JUNE 3, 2024
Top-Down Therapy Proves Its Worth in Crohn’s Disease
Adults newly diagnosed with active Crohn’s disease benefit from immediate treatment with advanced therapies, ...
APRIL 22, 2024
Advanced Therapy Combinations Show Promise in Treatment of IBD
Therapeutic strategies employing a combination of advanced therapies are starting to reveal promising outcomes in ...
JANUARY 15, 2024
How One IBD Patient Drove the Diagnosis of His Rare Therapy-Related Cancer
The story of Rob Thompson, an ulcerative colitis patient-turned-cancer survivor, is one of missed opportunities.
JANUARY 12, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 29, 2023
